194 related articles for article (PubMed ID: 24472477)
21. Pegylated liposomal doxorubicin as neoadjuvant therapy for stage II-III locally advanced breast cancer.
Yao J; Pan S; Fan X; Jiang X; Yang Y; Jin J; Liu Y
J Chemother; 2020 Jul; 32(4):202-207. PubMed ID: 32281493
[TBL] [Abstract][Full Text] [Related]
22. Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients.
Rocconi RP; Straughn JM; Leath CA; Kilgore LC; Huh WK; Barnes MN; Partridge EE; Alvarez RD
Oncologist; 2006 Apr; 11(4):336-41. PubMed ID: 16614229
[TBL] [Abstract][Full Text] [Related]
23. Long-term response to pegylated liposomal doxorubicin in patients with metastatic soft tissue sarcomas.
Grenader T; Goldberg A; Hadas-Halperin I; Gabizon A
Anticancer Drugs; 2009 Jan; 20(1):15-20. PubMed ID: 19342997
[TBL] [Abstract][Full Text] [Related]
24. Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long-term results from a single institution experience.
Martin-Romano P; Baraibar I; Espinós J; Legaspi J; López-Picazo JM; Aramendía JM; Fernández OA; Santisteban M
Breast J; 2018 Jul; 24(4):473-479. PubMed ID: 29286192
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in operable and locally advanced breast cancer.
Rossi D; Baldelli AM; Casadei V; Fedeli SL; Alessandroni P; Catalano V; Giordani P; Ceccolini M; Graziano F; Catalano G
Anticancer Drugs; 2008 Aug; 19(7):733-7. PubMed ID: 18594216
[TBL] [Abstract][Full Text] [Related]
26. Dose-dense nonpegylated liposomal Doxorubicin and docetaxel combination in breast cancer: dose-finding study.
Ricevuto E; Cocciolone V; Mancini M; Cannita K; Romano S; Bruera G; Pelliccione M; Adinolfi MI; Ciccozzi A; Bafile A; Penco M; Ficorella C
Oncologist; 2015 Feb; 20(2):109-10. PubMed ID: 25601964
[TBL] [Abstract][Full Text] [Related]
27. Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study.
Sparano JA; Makhson AN; Semiglazov VF; Tjulandin SA; Balashova OI; Bondarenko IN; Bogdanova NV; Manikhas GM; Oliynychenko GP; Chatikhine VA; Zhuang SH; Xiu L; Yuan Z; Rackoff WR
J Clin Oncol; 2009 Sep; 27(27):4522-9. PubMed ID: 19687336
[TBL] [Abstract][Full Text] [Related]
28. A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study.
Harbeck N; Saupe S; Jäger E; Schmidt M; Kreienberg R; Müller L; Otremba BJ; Waldenmaier D; Dorn J; Warm M; Scholz M; Untch M; de Wit M; Barinoff J; Lück HJ; Harter P; Augustin D; Harnett P; Beckmann MW; Al-Batran SE;
Breast Cancer Res Treat; 2017 Jan; 161(1):63-72. PubMed ID: 27798749
[TBL] [Abstract][Full Text] [Related]
29. Weekly non-pegylated liposomal doxorubicin chemotherapy in heavily pre-treated patients with metastatic breast cancer.
Masci G; Gandini C; Zuradelli M; Losurdo A; Torrisi R; Rota S; Gullo G; Velutti L; Giordano L; Santoro A
Anticancer Res; 2013 Oct; 33(10):4603-9. PubMed ID: 24123037
[TBL] [Abstract][Full Text] [Related]
30. Monitoring long-term treatment with pegylated liposomal doxorubicin: how important is intensive cardiac follow-up?
Grenader T; Goldberg A; Gabizon A
Anticancer Drugs; 2010 Oct; 21(9):868-71. PubMed ID: 20679886
[TBL] [Abstract][Full Text] [Related]
31. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).
Coleman RE; Biganzoli L; Canney P; Dirix L; Mauriac L; Chollet P; Batter V; Ngalula-Kabanga E; Dittrich C; Piccart M
Eur J Cancer; 2006 May; 42(7):882-7. PubMed ID: 16520033
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer.
Rom J; Bechstein S; Domschke C; Golatta M; Mayer C; Heil J; Thum J; Smetanay K; Windemuth-Kieselbach C; Wallwiener M; Marme F; Schuetz F; Sohn C; Schneeweiss A
Anticancer Drugs; 2014 Feb; 25(2):219-24. PubMed ID: 24247203
[TBL] [Abstract][Full Text] [Related]
33. Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients.
Ko EM; Lippmann Q; Caron WP; Zamboni W; Gehrig PA
Gynecol Oncol; 2013 Dec; 131(3):683-8. PubMed ID: 24096112
[TBL] [Abstract][Full Text] [Related]
34. Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial.
Fiegl M; Mlineritsch B; Hubalek M; Bartsch R; Pluschnig U; Steger GG
BMC Cancer; 2011 Aug; 11():373. PubMed ID: 21864402
[TBL] [Abstract][Full Text] [Related]
35. Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study.
Ardavanis A; Mavroudis D; Kalbakis K; Malamos N; Syrigos K; Vamvakas L; Kotsakis A; Kentepozidis N; Kouroussis C; Agelaki S; Georgoulias V;
Cancer Chemother Pharmacol; 2006 Dec; 58(6):742-8. PubMed ID: 16718470
[TBL] [Abstract][Full Text] [Related]
36. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut).
du Bois A; Pfisterer J; Burchardi N; Loibl S; Huober J; Wimberger P; Burges A; Stähle A; Jackisch C; Kölbl H; ;
Gynecol Oncol; 2007 Dec; 107(3):518-25. PubMed ID: 17910981
[TBL] [Abstract][Full Text] [Related]
37. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
Chia S; Clemons M; Martin LA; Rodgers A; Gelmon K; Pond GR; Panasci L
J Clin Oncol; 2006 Jun; 24(18):2773-8. PubMed ID: 16682726
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and toxicity of pegylated liposomal doxorubicin-based chemotherapy in early-stage breast cancer: a multicenter retrospective case-control study.
Yang FO; Hsu NC; Moi SH; Lu YC; Hsieh CM; Chang KJ; Chen DR; Tu CW; Wang HC; Hou MF
Asia Pac J Clin Oncol; 2018 Jun; 14(3):198-203. PubMed ID: 29045014
[TBL] [Abstract][Full Text] [Related]
39. Pegylated liposomal doxorubicin (Doxil) for metastatic breast cancer: the Cancer Research Network, Inc., experience.
Perez AT; Domenech GH; Frankel C; Vogel CL
Cancer Invest; 2002; 20 Suppl 2():22-9. PubMed ID: 12442346
[TBL] [Abstract][Full Text] [Related]
40. Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction.
Li Y; Finkel KW; Hu W; Fu S; Liu J; Coleman R; Kavanagh JJ
Gynecol Oncol; 2007 Aug; 106(2):375-80. PubMed ID: 17512575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
